p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors
p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors
About this item
Full title
Author / Creator
Publisher
Singapore: Springer Nature Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Nature Singapore
Subjects
More information
Scope and Contents
Contents
Targeting MDM2-p53 interaction has emerged as a promising antitumor therapeutic strategy. Several MDM2-p53 inhibitors have advanced into clinical trials, but results are not favorable. The lack of appropriate biomarkers for selecting patients has been assumed as the critical reason for this failure. We previously identified ZER6 isoform p52-ZER6 as...
Alternative Titles
Full title
p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9958181
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9958181
Other Identifiers
ISSN
1671-4083
E-ISSN
1745-7254
DOI
10.1038/s41401-022-00973-9
